Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 216

1.

High prevalence and incidence of rectal Chlamydia infection among men who have sex with men in Japan.

Mizushima D, Takano M, Uemura H, Yanagawa Y, Aoki T, Watanabe K, Gatanaga H, Kikuchi Y, Oka S.

PLoS One. 2019 Dec 10;14(12):e0220072. doi: 10.1371/journal.pone.0220072. eCollection 2019.

2.

Case Report: Acute Amebic Colitis Triggered by Colonoscopy: Exacerbation of Asymptomatic Chronic Infection with Entamoeba histolytica Accompanied by Dysbiosis.

Yanagawa Y, Arisaka T, Kawai S, Nakada-Tsukui K, Fukushima A, Hiraishi H, Chigusa Y, Gatanaga H, Oka S, Nozaki T, Watanabe K.

Am J Trop Med Hyg. 2019 Dec;101(6):1384-1387. doi: 10.4269/ajtmh.19-0396.

3.

Author Correction: CCR5AS lncRNA variation differentially regulates CCR5, influencing HIV disease outcome.

Kulkarni S, Lied A, Kulkarni V, Rucevic M, Martin MP, Walker-Sperling V, Anderson SK, Ewy R, Singh S, Nguyen H, McLaren PJ, Viard M, Naranbhai V, Zou C, Lin Z, Gatanaga H, Oka S, Takiguchi M, Thio CL, Margolick J, Kirk GD, Goedert JJ, Hoots WK, Deeks SG, Haas DW, Michael N, Walker B, Le Gall S, Chowdhury FZ, Yu XG, Carrington M.

Nat Immunol. 2019 Nov;20(11):1555. doi: 10.1038/s41590-019-0516-9.

PMID:
31548709
4.

Successful treatment for Kaposi sarcoma inflammatory cytokine syndrome in a severe CD4+ lymphocytopenic HIV patient.

Suzuki T, Uemura H, Yanagawa Y, Mizushima D, Aoki T, Watanabe K, Tanuma J, Tsukada K, Teruya K, Gatanaga H, Kikuchi Y, Oka S.

AIDS. 2019 Sep 1;33(11):1801-1802. doi: 10.1097/QAD.0000000000002201. No abstract available.

PMID:
31356257
5.

Comment on: Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study.

Gatanaga H, Oka S.

J Antimicrob Chemother. 2019 Nov 1;74(11):3402-3403. doi: 10.1093/jac/dkz301. No abstract available.

PMID:
31280307
6.

Identification of Immunodominant HIV-1 Epitopes Presented by HLA-C*12:02, a Protective Allele, Using an Immunopeptidomics Approach.

Chikata T, Paes W, Akahoshi T, Partridge T, Murakoshi H, Gatanaga H, Ternette N, Oka S, Borrow P, Takiguchi M.

J Virol. 2019 Aug 13;93(17). pii: e00634-19. doi: 10.1128/JVI.00634-19. Print 2019 Sep 1.

7.

CCR5AS lncRNA variation differentially regulates CCR5, influencing HIV disease outcome.

Kulkarni S, Lied A, Kulkarni V, Rucevic M, Martin MP, Walker-Sperling V, Anderson SK, Ewy R, Singh S, Nguyen H, McLaren PJ, Viard M, Naranbhai V, Zou C, Lin Z, Gatanaga H, Oka S, Takiguchi M, Thio CL, Margolick J, Kirk GD, Goedert JJ, Hoots WK, Deeks SG, Haas DW, Michael N, Walker B, Le Gall S, Chowdhury FZ, Yu XG, Carrington M.

Nat Immunol. 2019 Jul;20(7):824-834. doi: 10.1038/s41590-019-0406-1. Epub 2019 Jun 17. Erratum in: Nat Immunol. 2019 Nov;20(11):1555.

8.

Short Communication: A Quantitative System for Monitoring Blood-Circulating Viral Protein R of Human Immunodeficiency Virus-1 Detected a Possible Link with Pathogenic Indices.

Matsunaga A, Oka M, Iijima K, Shimura M, Gatanaga H, Oka S, Ishizaka Y.

AIDS Res Hum Retroviruses. 2019 Jul;35(7):660-663. doi: 10.1089/AID.2019.0016. Epub 2019 May 6.

PMID:
30938169
9.

Case report: new development of fibrosing interstitial lung disease triggered by HIV-related pneumocystis pneumonia.

Suzuki T, Shimoda Y, Teruya K, Gatanaga H, Kikuchi Y, Oka S, Watanabe K.

BMC Pulm Med. 2019 Mar 18;19(1):65. doi: 10.1186/s12890-019-0831-9.

10.

Effective Suppression of HIV-1 Replication by Cytotoxic T Lymphocytes Specific for Pol Epitopes in Conserved Mosaic Vaccine Immunogens.

Zou C, Murakoshi H, Kuse N, Akahoshi T, Chikata T, Gatanaga H, Oka S, Hanke T, Takiguchi M.

J Virol. 2019 Mar 21;93(7). pii: e02142-18. doi: 10.1128/JVI.02142-18. Print 2019 Apr 1.

11.

Case Report: Hemophagocytic Lymphohistiocytosis Caused by Disseminated Histoplasmosis in a Venezuelan Patient with HIV and Epstein-Barr Virus Reactivation Who Traveled to Japan.

Tsuboi M, Nishijima T, Nagi M, Miyazaki Y, Teruya K, Kikuchi Y, Gatanaga H, Oka S.

Am J Trop Med Hyg. 2019 Feb;100(2):365-367. doi: 10.4269/ajtmh.18-0478.

PMID:
30652668
12.

Full-Genome Analysis of Hepatitis C Virus in Japanese and Non-Japanese Patients Coinfected With HIV-1 in Tokyo.

Ishida Y, Hayashida T, Sugiyama M, Tsuchiya K, Kikuchi Y, Mizokami M, Oka S, Gatanaga H.

J Acquir Immune Defic Syndr. 2019 Mar 1;80(3):350-357. doi: 10.1097/QAI.0000000000001919.

PMID:
30550489
13.

The role of conventional antibodies targeting the CD4 binding site and CD4-induced epitopes in the control of HIV-1 CRF01_AE viruses.

Thida W, Kuwata T, Maeda Y, Yamashiro T, Tran GV, Nguyen KV, Takiguchi M, Gatanaga H, Tanaka K, Matsushita S.

Biochem Biophys Res Commun. 2019 Jan 1;508(1):46-51. doi: 10.1016/j.bbrc.2018.11.063. Epub 2018 Nov 20.

PMID:
30470571
14.

Benzolactam-related compounds promote apoptosis of HIV-infected human cells via protein kinase C-induced HIV latency reversal.

Matsuda K, Kobayakawa T, Tsuchiya K, Hattori SI, Nomura W, Gatanaga H, Yoshimura K, Oka S, Endo Y, Tamamura H, Mitsuya H, Maeda K.

J Biol Chem. 2019 Jan 4;294(1):116-129. doi: 10.1074/jbc.RA118.005798. Epub 2018 Nov 9.

15.

Increased risk of non-AIDS-defining cancers in Asian HIV-infected patients: a long-term cohort study.

Nagata N, Nishijima T, Niikura R, Yokoyama T, Matsushita Y, Watanabe K, Teruya K, Kikuchi Y, Akiyama J, Yanase M, Uemura N, Oka S, Gatanaga H.

BMC Cancer. 2018 Nov 6;18(1):1066. doi: 10.1186/s12885-018-4963-8.

16.

Broad Recognition of Circulating HIV-1 by HIV-1-Specific Cytotoxic T-Lymphocytes with Strong Ability to Suppress HIV-1 Replication.

Murakoshi H, Kuse N, Akahoshi T, Zhang Y, Chikata T, Borghan MA, Gatanaga H, Oka S, Sakai K, Takiguchi M.

J Virol. 2018 Dec 10;93(1). pii: e01480-18. doi: 10.1128/JVI.01480-18. Print 2019 Jan 1.

17.

Combination of a Latency-Reversing Agent With a Smac Mimetic Minimizes Secondary HIV-1 Infection in vitro.

Hattori SI, Matsuda K, Tsuchiya K, Gatanaga H, Oka S, Yoshimura K, Mitsuya H, Maeda K.

Front Microbiol. 2018 Sep 19;9:2022. doi: 10.3389/fmicb.2018.02022. eCollection 2018.

18.

Impact of a single HLA-A*24:02-associated escape mutation on the detrimental effect of HLA-B*35:01 in HIV-1 control.

Murakoshi H, Koyanagi M, Akahoshi T, Chikata T, Kuse N, Gatanaga H, Rowland-Jones SL, Oka S, Takiguchi M.

EBioMedicine. 2018 Oct;36:103-112. doi: 10.1016/j.ebiom.2018.09.022. Epub 2018 Sep 22.

19.

Usefulness of Automated Latex Turbidimetric Rapid Plasma Reagin Test for Diagnosis and Evaluation of Treatment Response in Syphilis in Comparison with Manual Card Test: a Prospective Cohort Study.

Tsuboi M, Nishijima T, Aoki T, Teruya K, Kikuchi Y, Gatanaga H, Oka S.

J Clin Microbiol. 2018 Oct 25;56(11). pii: e01003-18. doi: 10.1128/JCM.01003-18. Print 2018 Nov.

20.

CD8+ T cells specific for conserved, cross-reactive Gag epitopes with strong ability to suppress HIV-1 replication.

Murakoshi H, Zou C, Kuse N, Akahoshi T, Chikata T, Gatanaga H, Oka S, Hanke T, Takiguchi M.

Retrovirology. 2018 Jul 3;15(1):46. doi: 10.1186/s12977-018-0429-y.

21.

Tenofovir disoproxil fumarate co-administered with lopinavir/ritonavir is strongly associated with tubular damage and chronic kidney disease.

Mizushima D, Nguyen DTH, Nguyen DT, Matsumoto S, Tanuma J, Gatanaga H, Trung NV, van Kinh N, Oka S.

J Infect Chemother. 2018 Jul;24(7):549-554. doi: 10.1016/j.jiac.2018.03.002. Epub 2018 Mar 27.

PMID:
29602711
22.

Incomplete Recovery of CD4 Cell Count, CD4 Percentage, and CD4/CD8 Ratio in Patients With Human Immunodeficiency Virus Infection and Suppressed Viremia During Long-term Antiretroviral Therapy.

Mutoh Y, Nishijima T, Inaba Y, Tanaka N, Kikuchi Y, Gatanaga H, Oka S.

Clin Infect Dis. 2018 Aug 31;67(6):927-933. doi: 10.1093/cid/ciy176.

PMID:
29509894
23.

Prevalence and factors associated with chronic kidney disease and end-stage renal disease in HIV-1-infected Asian patients in Tokyo.

Nishijima T, Kawasaki Y, Mutoh Y, Tomonari K, Tsukada K, Kikuchi Y, Gatanaga H, Oka S.

Sci Rep. 2017 Nov 6;7(1):14565. doi: 10.1038/s41598-017-15214-x.

24.

Substantially Higher and Earlier Occurrence of Anti-Tuberculosis Drug-Related Adverse Reactions in HIV Coinfected Tuberculosis Patients: A Matched-Cohort Study.

Matono T, Nishijima T, Teruya K, Morino E, Takasaki J, Gatanaga H, Kikuchi Y, Kaku M, Oka S.

AIDS Patient Care STDS. 2017 Nov;31(11):455-462. doi: 10.1089/apc.2017.0116.

PMID:
29087745
25.

Interferon-free therapy with direct acting antivirals for HCV/HIV-1 co-infected Japanese patients with inherited bleeding disorders.

Uemura H, Tsukada K, Mizushima D, Aoki T, Watanabe K, Kinai E, Teruya K, Gatanaga H, Kikuchi Y, Sugiyama M, Mizokami M, Oka S.

PLoS One. 2017 Oct 18;12(10):e0186255. doi: 10.1371/journal.pone.0186255. eCollection 2017.

26.

Cumulative exposure of TDF is associated with kidney tubulopathy whether it is currently used or discontinued.

Nishijima T, Mutoh Y, Kawasaki Y, Tomonari K, Kikuchi Y, Gatanaga H, Oka S; ACC Study Team.

AIDS. 2018 Jan 14;32(2):179-188. doi: 10.1097/QAD.0000000000001667.

PMID:
29028660
27.

Control of HIV-1 by an HLA-B*52:01-C*12:02 Protective Haplotype.

Chikata T, Murakoshi H, Koyanagi M, Honda K, Gatanaga H, Oka S, Takiguchi M.

J Infect Dis. 2017 Dec 12;216(11):1415-1424. doi: 10.1093/infdis/jix483.

PMID:
28968792
28.

Time to development of ocular syphilis after syphilis infection.

Tsuboi M, Nishijima T, Yashiro S, Teruya K, Kikuchi Y, Katai N, Gatanaga H, Oka S.

J Infect Chemother. 2018 Jan;24(1):75-77. doi: 10.1016/j.jiac.2017.08.006. Epub 2017 Sep 25.

PMID:
28958728
29.

PCR detection of human herpesviruses in colonic mucosa of individuals with inflammatory bowel disease: Comparison with individuals with immunocompetency and HIV infection.

Shimada T, Nagata N, Okahara K, Joya A, Hayashida T, Oka S, Sakurai T, Akiyama J, Uemura N, Gatanaga H.

PLoS One. 2017 Sep 13;12(9):e0184699. doi: 10.1371/journal.pone.0184699. eCollection 2017.

30.

Colonic cytomegalovirus detection by mucosal PCR and antiviral therapy in ulcerative colitis.

Okahara K, Nagata N, Shimada T, Joya A, Hayashida T, Gatanaga H, Oka S, Sakurai T, Uemura N, Akiyama J.

PLoS One. 2017 Sep 8;12(9):e0183951. doi: 10.1371/journal.pone.0183951. eCollection 2017.

31.

High plasma concentrations of dolutegravir in patients with ABCG2 genetic variants.

Tsuchiya K, Hayashida T, Hamada A, Oki S, Oka S, Gatanaga H.

Pharmacogenet Genomics. 2017 Nov;27(11):416-419. doi: 10.1097/FPC.0000000000000308.

PMID:
28858994
32.

High-performance liquid chromatography-tandem mass spectrometry for simultaneous determination of raltegravir, dolutegravir and elvitegravir concentrations in human plasma and cerebrospinal fluid samples.

Tsuchiya K, Ohuchi M, Yamane N, Aikawa H, Gatanaga H, Oka S, Hamada A.

Biomed Chromatogr. 2018 Feb;32(2). doi: 10.1002/bmc.4058. Epub 2017 Aug 21.

PMID:
28762239
33.

Potential for immune-driven viral polymorphisms to compromise antiretroviral-based preexposure prophylaxis for prevention of HIV-1 infection.

Gatanaga H, Brumme ZL, Adland E, Reyes-Terán G, Avila-Rios S, Mejía-Villatoro CR, Hayashida T, Chikata T, Van Tran G, Van Nguyen K, Meza RI, Palou EY, Valenzuela-Ponce H, Pascale JM, Porras-Cortés G, Manzanero M, Lee GQ, Martin JN, Carrington MN, John M, Mallal S, Poon AFY, Goulder P, Takiguchi M, Oka S; International HIV Adaptation Collaborative.

AIDS. 2017 Sep 10;31(14):1935-1943. doi: 10.1097/QAD.0000000000001575.

PMID:
28650381
34.

Lifelong Prophylaxis With Trimethoprim-Sulfamethoxazole for Prevention of Outbreak of Pneumocystis jirovecii Pneumonia in Kidney Transplant Recipients.

Goto N, Takahashi-Nakazato A, Futamura K, Okada M, Yamamoto T, Tsujita M, Hiramitsu T, Narumi S, Tsuchiya K, Gatanaga H, Watarai Y, Oka S.

Transplant Direct. 2017 Apr 5;3(5):e151. doi: 10.1097/TXD.0000000000000665. eCollection 2017 May.

35.

Antiretroviral Therapy Containing HIV Protease Inhibitors Enhances Fracture Risk by Impairing Osteoblast Differentiation and Bone Quality.

Hirakawa H, Gatanaga H, Ochi H, Fukuda T, Sunamura S, Oka S, Takeda S, Sato S.

J Infect Dis. 2017 Jun 15;215(12):1893-1897. doi: 10.1093/infdis/jix246.

PMID:
28525596
36.

Emergence of CXCR4-tropic HIV-1 variants followed by rapid disease progression in hemophiliac slow progressors.

Hayashida T, Tsuchiya K, Kikuchi Y, Oka S, Gatanaga H.

PLoS One. 2017 May 4;12(5):e0177033. doi: 10.1371/journal.pone.0177033. eCollection 2017.

37.

Effect of Tenofovir Disoproxil Fumarate on Incidence of Chronic Kidney Disease and Rate of Estimated Glomerular Filtration Rate Decrement in HIV-1-Infected Treatment-Naïve Asian Patients: Results from 12-Year Observational Cohort.

Suzuki S, Nishijima T, Kawasaki Y, Kurosawa T, Mutoh Y, Kikuchi Y, Gatanaga H, Oka S.

AIDS Patient Care STDS. 2017 Mar;31(3):105-112. doi: 10.1089/apc.2016.0286.

38.

Protease inhibitor-associated bone mineral density loss is related to hypothyroidism and related bone turnover acceleration.

Kinai E, Gatanaga H, Mizushima D, Nishijima T, Aoki T, Genka I, Teruya K, Tsukada K, Kikuchi Y, Oka S.

J Infect Chemother. 2017 May;23(5):259-264. doi: 10.1016/j.jiac.2016.10.009. Epub 2017 Mar 6.

PMID:
28274549
39.

Incidence and Risk Factors for Incident Syphilis among HIV-1-Infected Men Who Have Sex with Men in a Large Urban HIV Clinic in Tokyo, 2008-2015.

Nishijima T, Teruya K, Shibata S, Yanagawa Y, Kobayashi T, Mizushima D, Aoki T, Kinai E, Yazaki H, Tsukada K, Genka I, Kikuchi Y, Oka S, Gatanaga H.

PLoS One. 2016 Dec 16;11(12):e0168642. doi: 10.1371/journal.pone.0168642. eCollection 2016.

40.

Accumulation of Pol Mutations Selected by HLA-B*52:01-C*12:02 Protective Haplotype-Restricted Cytotoxic T Lymphocytes Causes Low Plasma Viral Load Due to Low Viral Fitness of Mutant Viruses.

Murakoshi H, Koyanagi M, Chikata T, Rahman MA, Kuse N, Sakai K, Gatanaga H, Oka S, Takiguchi M.

J Virol. 2017 Jan 31;91(4). pii: e02082-16. doi: 10.1128/JVI.02082-16. Print 2017 Feb 15.

41.

HIV-1 Control by NK Cells via Reduced Interaction between KIR2DL2 and HLA-C12:02/C14:03.

Lin Z, Kuroki K, Kuse N, Sun X, Akahoshi T, Qi Y, Chikata T, Naruto T, Koyanagi M, Murakoshi H, Gatanaga H, Oka S, Carrington M, Maenaka K, Takiguchi M.

Cell Rep. 2016 Nov 22;17(9):2210-2220. doi: 10.1016/j.celrep.2016.10.075.

42.

Underestimated Amoebic Appendicitis among HIV-1-Infected Individuals in Japan.

Kobayashi T, Watanabe K, Yano H, Murata Y, Igari T, Nakada-Tsukui K, Yagita K, Nozaki T, Kaku M, Tsukada K, Gatanaga H, Kikuchi Y, Oka S.

J Clin Microbiol. 2016 Dec 28;55(1):313-320. doi: 10.1128/JCM.01757-16. Print 2017 Jan.

43.

Identification of two unique naturally occurring Vpr sequence polymorphisms associated with clinical parameters in HIV-1 chronic infection.

Kamori D, Hasan Z, Ohashi J, Kawana-Tachikawa A, Gatanaga H, Oka S, Ueno T.

J Med Virol. 2017 Jan;89(1):123-129. doi: 10.1002/jmv.24612. Epub 2016 Jul 6.

PMID:
27328918
44.

Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection.

Murata K, Asano M, Matsumoto A, Sugiyama M, Nishida N, Tanaka E, Inoue T, Sakamoto M, Enomoto N, Shirasaki T, Honda M, Kaneko S, Gatanaga H, Oka S, Kawamura YI, Dohi T, Shuno Y, Yano H, Mizokami M.

Gut. 2018 Feb;67(2):362-371. doi: 10.1136/gutjnl-2016-312653. Epub 2016 Oct 27.

45.

Cerebral Syphilitic Gumma within 5 Months of Syphilis in HIV-Infected Patient.

Tsuboi M, Nishijima T, Teruya K, Kikuchi Y, Gatanaga H, Oka S.

Emerg Infect Dis. 2016 Oct;22(10):1846-8. doi: 10.3201/eid2210.160600. No abstract available.

46.

The Prevalence of High Antiretroviral Coverage and Viral Suppression in Japan: an Excellent Profile for a Downstream Human Immunodeficiency Virus Care Spectrum.

Miyazaki N, Sugiura W, Gatanaga H, Watanabe D, Yamamoto Y, Yokomaku Y, Yoshimura K, Matsushita S; Japanese HIV-MDR Study Group.

Jpn J Infect Dis. 2017 Mar 24;70(2):158-160. doi: 10.7883/yoken.JJID.2015.599. Epub 2016 Jun 30.

47.

Rilpivirine resistance mutation E138K in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations.

Hayashida T, Hachiya A, Ode H, Nishijima T, Tsuchiya K, Sugiura W, Takiguchi M, Oka S, Gatanaga H.

J Antimicrob Chemother. 2016 Oct;71(10):2760-6. doi: 10.1093/jac/dkw224. Epub 2016 Jun 20.

PMID:
27330069
48.

Increases in Entamoeba histolytica Antibody-Positive Rates in Human Immunodeficiency Virus-Infected and Noninfected Patients in Japan: A 10-Year Hospital-Based Study of 3,514 Patients.

Yanagawa Y, Nagata N, Watanabe K, Tsukada K, Teruya K, Kikuchi Y, Gatanaga H, Akiyama J, Uemura N, Oka S.

Am J Trop Med Hyg. 2016 Sep 7;95(3):604-609. doi: 10.4269/ajtmh.16-0134. Epub 2016 Jun 13.

49.

Effects of a Single Escape Mutation on T Cell and HIV-1 Co-adaptation.

Sun X, Shi Y, Akahoshi T, Fujiwara M, Gatanaga H, Schönbach C, Kuse N, Appay V, Gao GF, Oka S, Takiguchi M.

Cell Rep. 2016 Jun 7;15(10):2279-2291. doi: 10.1016/j.celrep.2016.05.017. Epub 2016 May 26.

50.

Brief Report: High Peak Level of Plasma Raltegravir Concentration in Patients With ABCB1 and ABCG2 Genetic Variants.

Tsuchiya K, Hayashida T, Hamada A, Oka S, Gatanaga H.

J Acquir Immune Defic Syndr. 2016 May 1;72(1):11-4. doi: 10.1097/QAI.0000000000000893.

PMID:
27097364

Supplemental Content

Loading ...
Support Center